Aktueller Artikel im Beacon www.myelomabeacon.com/news/2013/08/19/be...shes-august-19-2013/

Kurzfassung: Die 11;14 Translokation ist bei Abwesenheit des CD20 Eiweiß eher ein Indiz für eine schlechte Prognose.

Deckt sich leider mit meiner persönlichen Erfahrung, daß 11;14 doch nicht egal oder eher gut für die Prognose ist.


Presence Of Protein CD20 May Predict Disease Outcome In Myeloma Patients With Chromosomal Abnormality t(11;14) – Chinese researchers have recently found that myeloma patients with the chromosomal abnormality t(11;14) may show normal or poor disease outcome depending upon the presence of a protein called CD20. After Velcade (bortezomib)-based treatment, patients whose myeloma cells contained both t(11;14) and the CD20 protein showed significantly longer progression-free survival than patients who had t(11;14) without CD20 (43 months versus 11 months). Overall survival was also longer in patients whose myeloma cells had CD20 as compared to patients without CD20 (54 months versus 17 months). Although t(11;14) is the most common chromosomal abnormality seen in myeloma cells, its impact on treatment outcome has remained controversial (see related Beacon news). In general, patients with t(11;14) are not classified as having high-risk disease. As a caveat, findings from this China-based study may not be directly applicable to myeloma patients of other ethnicities and will therefore require further validation. For more information, please see the study in Leukemia Research (abstract).